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Primary ciliary dyskinesia (PCD) is a genetically heterogeneous, autosomal
recessive disorder that results from functional and ultrastructural abnormalities
of motile cilia. Patients with PCD have diverse clinical phenotypes that include
chronic upper and lower respiratory tract infections, situs inversus, heterotaxy
with or without congenital heart disease, and male infertility, among others. In
this report, the carrier frequencies for eleven mutations in eight PCD-associated
genes (DNAI1, DNAI2, DNAH5, DNAH11, CCDC114, CCDC40, CCDC65, and
C21orf59) that had been found in individuals of Ashkenazi Jewish descent were
investigated in order to advise on including them in existing clinical mutation
panels for this population. Results showed relatively high carrier frequencies for
the DNAH5 c.7502G>C mutation (0.58%), the DNAI2 c.1304G>A mutation
(0.50%), and the C21orf59 c.735C>G mutation (0.48%), as well as lower fre-
quencies for mutations in DNAI1, CCDC65, CCDC114, and DNAH11 (0.10–
0.29%). These results suggest that several of these genes should be considered
for inclusion in carrier screening panels in the Ashkenazi Jewish population.
Introduction
Primary ciliary dyskinesia (PCD, MIM: 244400) is a
genetically heterogeneous, autosomal recessive disorder
that results from functional and ultrastructural abnor-
malities of motile cilia. Phenotypes of PCD can be
diverse, with irregularities in motile respiratory cilia
causing chronic upper and lower respiratory tract infec-
tions, in embryonic nodal cilia causing situs inversus
and heterotaxy with or without congenital heart disease,
and in spermatozoa flagella causing male infertility,
among others clinical features (Zariwala et al. 2007;
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Escudier et al. 2009; Leigh et al. 2009; Knowles et al.
2013a). PCD can be diagnosed in various manners
including the detection of ultrastructural defects by
transmission electron microscopy, abnormal ciliary beat
frequencies or patterns, low levels of nasal nitric oxide,
the presentation of typical clinical features, and muta-
tion analysis in ciliary genes (Zariwala et al. 2007; Escu-
dier et al. 2009; Leigh et al. 2009, 2013; Knowles et al.
2013a; Svobodova et al. 2013).
Primary ciliary dyskinesia has extensive locus and allelic
heterogeneity that makes it challenging for genetic diag-
noses. Due to the high number of causative PCD muta-
tions, tiered mutation screening methods have been
suggested for PCD patients (Hornef et al. 2006; Zariwala
et al. 2006; Djakow et al. 2012). In tiered screenings,
mutations are ranked based on their prevalence in the
PCD population, with the most common mutations
screened first in an effort to increase efficiency. Founder
effects have resulted in certain recessive mutations to
appear more frequently in specific ethnic populations as
well, which allows for a different ranking system to be
made based on the frequency of mutations in a specific
ethnic group or geographic isolates. An example of such
effects has been seen in PCD where a splice-site mutation
in RSPH4A (MIM 612649, 612647) is found in people of
Hispanic origin from Puerto Rico (Daniels et al. 2013).
Since the Ashkenazi Jewish population has an increased
prevalence of recessive mutations due to past founder
effects (Bray et al. 2010), carrier frequencies were per-
formed for eleven mutations in eight PCD genes that had
been observed in affected individuals of Ashkenazi Jewish
descent in order to advise on screening for them.
Of the 11 mutations evaluated, six were in four genes
known to cause defective ciliary outer dynein arm (ODA)
complexes (Hornef et al. 2006; Zariwala et al. 2006;
Knowles et al. 2013b). These included mutations in
DNAI1 (OMIM# 604366) (NM_012144.2) c.1490G>A
(r.1402_1569del) (p.Arg468_Lys523del) (Zariwala et al.
2006), DNAI2 (OMIM# 605483) (NM_023036.4)
c.1304G>A (p.Trp435*) (Knowles et al. 2013b),
CCDC114 (OMIM# 615038) (NM_144557.3) c.939delT
(p.His313Glnfs*14) (Knowles et al. 2013b), and three in
DNAH5 (OMIM# 603335) (NM_001369.2): c.7502G>C
(p.Arg2501Pro) (Hornef et al. 2006), novel c.5545G>A
(p.Ala1849Thr) and novel c.6988+2T>C (g.IVS42+2T>C)
(p. splice?). Two of the remaining mutations were in
CCDC40 (OMIM# 613799) (NM_017950.3) c.248delC
(p.Ala83Valfs*84) (Becker-Heck et al. 2011; Antony et al.
2012) which causes defective inner dynein arm (IDA) com-
plexes together with microtubular disorganization in a
subset of cilia, and C21orf59 (OMIM# 615494)
(NM_021254.2) c.735C>G (p.Tyr245*) (Austin-Tse et al.
2013) which causes the absence of both ODAs and IDAs.
The remaining three mutations were from two genes that
do not cause any detectable ciliary ultrastructural defects
(Schwabe et al. 2008; Knowles et al. 2012; Austin-Tse et al.
2013; Horani et al. 2013) and included the c.877_878delAT
(p.Ile293Profs*2) in CCDC65 (OMIM# 611088)
(NM_033124.4) (Austin-Tse et al. 2013; Horani et al.
2013) and two mutations in DNAH11(OMIM# 603339) (NM_
001277115.1): c.6244C>T (p.Arg2082*) and c.11929G>T
(p.Glu3977*) (Knowles et al. 2012).
Materials and Methods
Ethics statement
The samples used in this study were obtained with writ-
ten patient consent from self-identified Ashkenazi Jews
enrolled in the carrier testing Dor Yeshorim program
(Ekstein and Katzenstein 2001) to be used for research
purposes. Consent form information included that patient
material would be used for clinical testing and that excess
material would be de-identified and used for research
purposes to characterize single-gene disorders in the
Ashkenazi Jewish population. The positive control sam-
ples came from the Institutional review board approved
research cohort for the protection of the rights of human
subjects that were recruited under the auspices of the
Genetic Disorders of Mucociliary Clearance consortium.
Institutional review board permission was not required
for the control samples used in the carrier frequency
study because all sample identifiers were removed prior
to receipt by the laboratory where the TaqMan assays
were carried out (45 CFR part 46.101(b)(4)).
Patients
The positive control samples came from the individuals
harboring mutations who self-identified as being from
an Ashkenazi Jewish descent. The genotypes for the
majority of the positive controls for the mutations in
DNAH11 (NM_001277115.1), DNAI1 (NM_012144.2),
DNAI2 (NM_023036.4), CCDC114 (NM_144577.3),
CCDC40 (NM_017950.3), C21orf59 (NM_021254.2), and
CCDC65 (NM_033124.4) have previously been pub-
lished (Zariwala et al. 2006; Antony et al. 2012; Know-
les et al. 2012; Austin-Tse et al. 2013; Knowles et al.
2013b). In addition, for the previously known
c.7502G>C missense mutation (Hornef et al. 2006)and
a novel c.6988+2T>C splice-site mutation in DNAH5
(NM_001369.2), we used gDNA from the affected indi-
vidual (#826), who harbored both mutations. Individual
#826 had an affected sibling with the identical DNAH5
genotypes and both unaffected parents were carriers;
thus, indicating both mutations in the affected individ-
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uals were inherited in trans. For the c.5545G>A muta-
tion in DNAH5, the gDNA from an unaffected carrier
mother of Ashkenazi descent was used. This mutation
was observed in a PCD affected individual who har-
bored a splice-site mutation on the trans allele that was
inherited from a non-Ashkenazi unaffected father; thus
the splice-site mutation was not evaluated.
Assay design and validation
To design the genotyping assays, the full sequence of each
gene was obtained from the National Center for Biotech-
nology Information (NCBI) (U.S. National Library of
Medicine, Bethesda, MD). Roughly 200 base pairs
upstream and downstream of the mutation site were
selected and repetitive sequences and SNPs were masked
using Repeat Masker (Institute for Systems Biology, Seat-
tle, WA) and NCBI specialized Basic Local Alignment
Search Tool (BLAST) using the SNP Flanks option,
respectively. The assays were then made in File Builder
software (Life Technologies [LTI], Carlsbad, CA) with
sequence-specific forward and reverse primers to amplify
the polymorphic sequences, and VIC and FAM fluores-
cent-labeled probes to detect the normal and mutant
alleles, respectively (Table 1). A no template control con-
sisting of water, three wild-type samples, and one known
heterozygous carrier sample were used to validate all of
the assays except for the CCDC40 assay which was vali-
dated on homozygous affected gDNA. The genotypes for
all of the control samples were confirmed using Sanger
Sequencing. The samples and assays were plated in dupli-
cate in a 384 well plate along with TaqMan Genotyping
Master Mix (LTI) (final volume 5 lL) and run in duplex
real-time PCR reactions followed by allelic discrimination
on the ABI PRISM 7900 HT Sequence Detection System
using SDS 2.3 software (LTI).
Carrier frequency study
For the carrier frequency study, ~1000 samples were ana-
lyzed for each mutation. The gDNA samples were not
normalized prior to plating, but almost all samples fell
within the suggested range of 1–20 ng (LTI). The plates
were run on the GeneAmp PCR System 9700 (LTI) at
the following setting: holds at 50°C for 2 min and 95°C
for 10 min, and then 40 cycles at 95°C for 15 sec and
60°C for 1 min. Allelic discrimination was then per-
formed on the ABI PRISM 7900 HT Sequence Detection
System using SDS 2.3 software and the data were analyzed
using TaqMan Genotyper v1.1 software (LTI). Any sam-
ples that did not amplify were not included in the carrier
frequency calculations. The samples from the initial
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val (Wilson 1927) was used to calculate the confidence
intervals (CI) for carrier frequencies.
Results
The initial validation of the assays on a small scale yielded
100% genotyping accuracy. The carrier frequency experi-
ments were then performed on ~1000 samples from indi-
viduals of Ashkenazi Jewish descent. The carrier frequency
results were as follows: 0.28% (CI 0.09–0.83%) for the
DNAI1 c.1490G>A mutation, 0.50% (CI 0.21–1.16%) for
the DNAI2 c.1304G>A mutation, 0.10% (CI 0.02–0.54%)
for the DNAH11 c.11929G>T mutation, 0.58% (CI 0.27–
1.26%) for the DNAH5 c.7502G>C mutation, 0.19% (CI
0.05–0.69%) for the CCDC114 c.939delT mutation, 0.29%
(CI 0.10–0.85%) for the CCDC65 c.877_878delAT muta-
tion, and 0.48% (CI 0.20–1.12%) for the C21orf59
c.735C>G mutation. No carriers were detected for the
DNAH5 c.6988+2T>C and c.5545G>A, the DNAH11
c.6244C>T, or the CCDC40 c.248delC mutations. TaqMan
allelic discrimination result plots can be seen in Figure 1
for all of the mutations, and a summary of the carrier fre-
quencies can be seen in Table 2. Samples identified as being
heterozygous carriers were confirmed by Sanger Sequencing
(if gDNA was available), and all genotypes were concordant
between the two methods.
Discussion
Because of the extensive heterogeneous nature of PCD,
knowing if certain mutations are more prevalent in a spe-
cific ethnic population can help prioritize variants for
expeditious screening. In this study, 11 different muta-
tions represented by eight genes that had all been
previously found in individuals of Ashkenazi Jewish
descent were examined. Of these, seven mutations repre-
Figure 1. Carrier frequency allelic discrimination plots. For all plots, the VIC probe (wild-type allele) is represented by the X-axis, and the FAM
probe (mutant allele) is represented by the Y-axis. Sterile water was used as the no template control. The GenBank reference sequence and
version number for the genes studied are as follows: DNAI1 (NM_012144.2), DNAI2 (NM_023036.4), DNAH11 (NM_001277115.1), DNAH5
(NM_001369.2), CCDC40 (NM_017950.3), CCDC65 (NM_033124.4), CCDC114 (NM_144577.3), and C21orf59 (NM_021254.2).
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senting seven genes were found to have carrier frequencies
ranging from 0.1% to 0.58% in the population.
Of all the mutations screened, the highest frequency
(0.58%) was found for the c.7502G>C mutation in the
DNAH5 gene. Mutations in this gene are the most com-
mon in PCD patients in the general population (Hornef
et al. 2006; Failly et al. 2009), accounting for 28% of all
PCD families and 49% of PCD families that have ODA
defects (Zariwala et al. 2007). The 0.48% frequency of
the c.735C>G mutation in C21orf59 and the 0.29% for
the c.877_878delAT mutation in CCDC65 are believed
to be founder mutations, which explains their relatively
high frequencies (Austin-Tse et al. 2013). The 0.29%
carrier frequency for the c.877_878delAT CCDC65 was
slightly lower than the 0.41% previously detected in this
population (Horani et al. 2013), which may reflect that
this study was conducted on the orthodox as opposed
to the general Ashkenazi population. Other mutations
that had been previously reported to be at mutation
hotspots for PCD patients had no carriers detected, such
as the c.248delC mutation in CCDC40 (Antony et al.
2012).
Based on the various frequencies found, we suggest that
the seven mutations that had carriers detected be recom-
mended for inclusion in mutation screening panels specific
for the Ashkenazi population since there is a chance of
compound heterozygosity based on the prevalence of the
various mutations. While none of the mutations meet the
inclusion criteria of a 1% frequency set by the American
College of Medical Genetics (ACMG) (Gross et al. 2008)
the advances made in high-throughput screening programs
(Fedick et al. 2013) have made screening for additional
and/or rare mutations possible and affordable, with many
commercial laboratories already offering ethnic screening
panels that extend beyond the scope of mutations specifi-
cally recommended by the ACMG and other such organi-
zations (Lazarin et al. 2013) Since the ACMG, along with
the American College of Obstetricians and Gynecologists,
has acknowledged that individuals may want to be
screened for additional disorders, we suggest that informa-
tion for all of the PCD genes and mutations studied here
be made available when receiving genetic counseling to aid
patients in making informed decisions (Monaghan et al.
2008; ACOG Committee on Genetics 2009).
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Carrier frequency (%) and
confidence interval (%)
DNAI1 c.1490G>A 1052 3 0.28 (0.09–0.83)
DNAI2 c.1304G>A 1000 5 0.50 (0.21–1.16)
DNAH11 c.6244C>T 1052 0 0.00
DNAH11 c.11929G>T 1051 1 0.10 (0.02–0.54)
DNAH5 c.6988+2T>C 1050 0 0.00
DNAH5 c.7502G>C 1036 6 0.58 (0.27–1.26)
DNAH5 c.5545G>A 1051 0 0.00
CCDC40 c.248delC 1052 0 0.00
CCDC65 c.877_878delAT 1032 3 0.29 (0.10–0.85)
CCDC114 c.939delT 1054 2 0.19 (0.05–0.69)
C21orf59 c.735C>G 1031 5 0.48 (0.20–1.12)
1None of the individuals were identified as being homozygous for the mutations.
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